ABIVAX successfully completes first-in-man study of ABX464, a highly differentiated small molecule targeting HIV
AXB464 is a small molecule with the potential to inhibit HIV replication. Through its unique mode of action, ABX464 is the first anti-HIV drug able to induce a long-lasting HIV viral load reduction even after treatment has been stopped, in pre-clinical testing in mice. ABX464 has also shown an absence of resistance in vitro.
ABX464 is the first candidate molecule coming from ABIVAX’s proprietary technology platform and chemical library, generated from its deep understanding of the processing of viral RNA within the human host cell and the ability of compounds from its novel library to inhibit RNA-protein interactions. This platform allows ABIVAX to potentially address a broad range of viral targets.
The successful first-in-man trial of ABX464 in healthy volunteers assessed pharmacokinetic properties and biological safety. The Phase 1 study was completed with single administration of 4 doses: 50, 100, 150 and 200mg, and saw no serious adverse event and no clinically significant abnormal result in physical examinations, laboratory test results, vital signs and ECG.
ABIVAX plans to start a Phase 2 study in patients with HIV in the coming months.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.